High dose methotrexate therapy: Insecure rationale?
- 15 July 1988
- journal article
- editorial
- Published by Elsevier in Biochemical Pharmacology
- Vol. 37 (14), 2713-2715
- https://doi.org/10.1016/0006-2952(88)90032-9
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Methotrexate (MTX) concentration in tumors following low-dose MTXCancer Chemotherapy and Pharmacology, 1987
- Methotrexate resistance and gene amplification. Mechanisms and implicationsCancer, 1986
- Heterogeneity in the specific activity and methotrexate sensitivity of dihydrofolate reductase from blast cells of acute myelogenous leukemia patients.Journal of Clinical Oncology, 1985
- Lack of Dihydrofolate Reductase in Human Tumor and Leukemia CellsIn VivoCancer Drug Delivery, 1985
- Detection by high-performance liquid chromatography of methotrexate and its metabolites in tumor tissue from osteosarcoma patients treated with high-dose methotrexate/leucovorin rescueBiochemical Pharmacology, 1984
- Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma.Journal of Clinical Oncology, 1984
- Gene amplification in a leukemic patient treated with methotrexate.Journal of Clinical Oncology, 1984
- Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: A safe new effective regimenCancer, 1981
- Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapyCancer, 1973
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)New England Journal of Medicine, 1948